Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone Administration

Nuclear Medicine and Molecular Imaging

Volumn 49, Issue 4, 2015, Pages 268-275

  Son, Seung Hyun ^a   Lee, Sang Woo ^a   Jung, Ji hoon ^a   Kim, Choon Young ^a   Kim, Do Hoon ^a   Jeong, Shin Young ^a   Ahn, Byeong Cheol ^a   Lee, Jaetae ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Differentiated thyroid cancer; Recombinant human thyroid stimulating hormone; RhTSH; Thyroid cancer; Thyrotropin

Indexed keywords

CREATININE; RECOMBINANT THYROTROPIN; THYROTROPIN;

ADULT; AGED; ARTICLE; BODY MASS; FEMALE; FOLLOW UP; GAMMA COUNTER; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOACTIVITY; RETROSPECTIVE STUDY; THYROID CANCER; THYROIDECTOMY; UREA NITROGEN BLOOD LEVEL;

EID: 84958157929     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-015-0348-y     Document Type: Article

References (28)

1. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocr Metab. 2003;88:1433–41.
2. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150:105–12.
3. Dietlein M, Busemeyer S, Kobe C, Schmidt M, Theissen P, Schicha H. Recombinant human TSH versus hypothyroidism. cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma. Nuklearmedizin. 2010;49:216–24.
4. Heinzel A, Kley K, Mueller HW, Hautzel H. A comparison of rh-TSH and thyroid hormone withdrawal in patients with differentiated thyroid cancer: preliminary evidence for an influence of age on the subjective well-being in hypothyroidism. Horm Metab Res. 2012;44:54–9.
5. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20:173–9.
6. Chow SM, Au KH, Choy TS, Lee SH, Yeung NY, Leung A, et al. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning. Laryngoscope. 2006;116:2060–6.
7. Sanchez R, Espinosa-de-los-Monteros AL, Mendoza V, Brea E, Hernandez I, Sosa E, et al. Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma. Arch Med Res. 2002;33:478–81.
8. Serhal DI, Nasrallah MP, Arafah BM. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. J Clin Endocr Metab. 2004;89:3285–9.
9. Pacini F, Castagna MG. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2008;22:1009–21.
10. Castagna MG, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P, et al. Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. J Clin Endocr Metab. 2005;90:4047–50.
11. Hautzel H, Pisar E, Lindner D, Schott M, Grandt R, Muller HW. Impact of renal function and demographic/anthropomorphic variables on peak thyrotropin after recombinant human thyrotropin stimulation: a stepwise forward multiple-regression analysis. Thyroid. 2013;23:662–70.
12. Montesano T, Durante C, Attard M, Crocetti U, Meringolo D, Bruno R, et al. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. Biomed Pharmacother. 2007;61:468–71.
13. Over R, Nsouli-Maktabi H, Burman KD, Jonklaas J. Age modifies the response to recombinant human thyrotropin. Thyroid. 2010;20:1377–84.
14. Vitale G, Lupoli GA, Ciccarelli A, Lucariello A, Fittipaldi MR, Fonderico F, et al. Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration. J Clin Endocr Metab. 2003;88:1319–22.
15. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303–11. discussion 12-3.
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YP, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.
17. Bakke J, Lawrence N, Roy S. Disappearance rate of exogenous thyroid-stimulating hormone (TSH) in man. J Clin Endocr Metab. 1962;22:352–63.
18. Cuttelod S, Lemarchand-Beraud T, Magnenat P, Perret C, Poli S, Vannotti A. Effect of age and role of kidneys and liver on thyrotropin turnover in man. Metabolism. 1974;23:101–13.
19. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006;52:5–18.
20. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.
21. Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. J Endocrinol Invest. 1999;22(11 Suppl):30–4.
22. Luster M, Reinhardt W, Korber C, Lassmann M, Haenscheid H, Michalowski U, et al. The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J Endocrinol Invest. 2000;23:473–5.
23. Jarzab B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging. 2003;30:1077–86.
24. Adler ML, Macapinlac HA, Robbins RJ. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Pract. 1998;4:282–6.
25. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol. 2001;144:5–11.
26. Vargas GE, Uy H, Bazan C, Guise TA, Bruder JM. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocr Metab. 1999;84:3867–71.
27. Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocr Metab. 2001;86:5148–51.
28. Valle LA, Gorodeski Baskin RL, Porter K, Sipos JA, Khawaja R, Ringel MD, et al. In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 µU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin. Thyroid. 2013;23:185–93.